Aimovig is a specialized treatment designed to help prevent migraines in adult patients who experience them frequently. By targeting the calcitonin gene-related peptide (CGRP) receptor, which is thought to play a key role in migraine attacks, this medication offers a proactive approach to reducing the frequency and impact of migraines on your daily life. This product comes in a convenient, single-use pre-filled pen designed for subcutaneous administration. Aimovig is intended for patients who may benefit from a targeted preventive therapy, helping to provide a clearer, more comfortable path forward by addressing the underlying mechanisms associated with migraine onset.

3. How to Use

Aimovig is administered via a subcutaneous injection using the provided single-use pre-filled pen. It is intended for self-administration or administration by a caregiver after proper training by a healthcare provider. Before injecting, ensure the solution is clear and colorless to slightly yellow; do not use if it appears cloudy or discolored. Choose an injection site such as the abdomen, thigh, or upper arm, and follow the specific step-by-step instructions included in the patient information leaflet or provided by your doctor. Always store the pre-filled pen in a refrigerator, but allow it to reach room temperature for 30 minutes before use to ensure a more comfortable injection experience.

4. Key Benefits

Targeted prevention of migraine attacks | Convenient single-use pre-filled pen format | Suitable for subcutaneous administration | Engineered to block CGRP receptors | Helps reduce the frequency of migraines

5. Certifications

• Active Ingredient: Erenumab (70mg/mL)
• Administration: Subcutaneous use only
• Packaging: Single-use pre-filled pen
• Manufacturer: Novartis